Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs on Feb. 12)
- Abbott Laboratories ABT
- Amphastar Pharmaceuticals Inc AMPH
- Biohaven Pharmaceutical Holding Co Ltd BHVN
- Boston Scientific Corporation BSX
- Edwards Lifesciences Corp EW(CASM) for $100 million)
- Masimo Corporation MASI
- Mirati Therapeutics Inc MRTX
Down In The Dumps
(Biotech stocks hitting 52-week lows on Feb. 12)
- CELLECT BIOTECH/S ADR APOP
- Collegium Pharmaceutical Inc COLL
- Organogenesis Holdings Inc ORGO
- Scpharmaceuticals Inc SCPH
Stock In Focus
Exelixis Q4 Exceeds Expectations
Exelixis, Inc. EXEL reported fourth-quarter non-GAAP EPS of 37 cents per share. Total revenues climbed from $120.1 million to $228.6 million, helped by strong Cabozantinib franchise net revenues, which climbed 84 percent year-over-year to $176.2 million. The results beat consensus estimates, which called for EPS of 24 cents on revenues of $188.76 million.
The stock rallied 7.38 percent to $23.28 in after-hours trading.
MacroGenics Price Of Common Stock Offering At A Discount
MacroGenics Inc MGNX priced its public offering of 5.50 million shares at $20 per share. The company expects total proceeds from the offering of $110 million.
The stock slipped 1.62 percent to $20.65 in after-hours trading.
Vistagen Q3 Loss Wider Than Expected
Vistagen Therapeutics Inc VTGN, which has an investigational depression drug in its pipeline, reported a third-quarter loss of 24 cents per share compared to a loss of 25 cents per share a year ago. Analysts estimated a narrower loss of 22 cents per share.
The stock declined 3.41 percent to $1.70 in after-hours trading.
FDA Panel OKs J&J's Treatment-Resistant Depression Drug
Johnson & Johnson JNJ's Janssen unit said a joint meeting of FDA's Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk Management Advisory Committee voted in favor of the benefit-risk profile of Esketamine nasal spray for adults with treatment-resistant depression, with 14 giving a thumbs up, 2 against and 1 member abstaining.
The PDUFA date for the pipeline asset is set for March 4.
See Also: Gilead Analysts React To Failed NASH Trial: Citigroup, Wells Fargo Downgrade Biotech
Moderna Reports Positive Early-Stage Results For Respiratory Infection Vaccine
Moderna Inc MRNA announced positive topline results from the first planned interim analysis of safety and immunogenicity from a Phase 1 study of mRNA-1653 in healthy adults.
mRNA is being evaluated as a prophylactic vaccine against t human metapneumovirus (hMPV) and parainfluenza type 3 (PIV3), two viruses that cause respiratory infections, and is a combo vaccine that consists of two direct mRNA sequences encoding the fusion proteins of hMPV and PIV3 formulated in Moderna's proprietary lipid nanoparticle technology.
The interim results showed a single vaccination boosted serum neutralization titers against hMPV and PIV3, and that the magnitude of the boost was similar at all dose levels tested. The study also showed a single vaccination was sufficient to achieve a plateau in neutralizing antibodies in pre-exposed population. It was also found to be safe and generally well tolerated.
On The Radar
PDUFA Date
The FDA is set to rule on MOTIF BIO PLC/S ADR MTFB's NDA for Iclaprim to acute bacterial skin and skin structure infections, or ABSSSI.
Earnings
Ironwood Pharmaceuticals, Inc. IRWD Q4 EPS $(0.10) Beats $(0.15) Estimate, Sales $130.69M Beat $98.47M Estimate
Natus Medical Inc BABY Q4 Adj. EPS $0.43 Misses $0.49 Estimate, Sales $141M Beat $136.65M Estimate
Vanda Pharmaceuticals Inc. VNDA (after the market close)
Urovant Sciences Ltd UROV (after the market close)
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.